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Abstract 
Fibulin-2 is an extracellular matrix glycoprotein 
with an important function in maintaining elastic 
properties in different tissues. Fibulin-2 belongs to 
a protein family with seven members characterized 
by sharing a globular domain at the carboxy-
terminus, which is called "fibulin-like", "FC 
domain" or domain III. Together with fibulin-1, 
fibulin-2 forms the so called subgroup 1 in the 
fibulin family which contains three anaphylatoxin 
modules in their sequence. Fibulin-2 does not only 
form part of elastic fibers but is also present in 
basement membranes and other connective tissue 
structures. Besides its structural function, 
alterations in fibulin-2 expression have also been 
related to several pathological processes. Thus, 
fibulin-2 has been shown to be implicated in blood 
pressure regulation, vascular injury protection or 
with a protective role in some heart malfunctioning. 
Also, fibulin-2 participation has been described in 
cancer showing both oncogenic or tumor-
suppressor properties. 
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Identity 
HGNC (Hugo): FBLN2 
Location : 3p25.1 
DNA/RNA 
According to NCBI (National Center for 
Biotechnology Information) fibulin-2 
(NC_000003.12) is encoded in 19 exons in 
chromosome 3, spans approximately 89.3 Kb of 
genomic DNA in the telomere-to-centromere 
orientation.  
The translation initiation codon is located to exon 3, 
and the stop codon to exon 19. 
Transcription 
Northern blot analysis of mRNA from various 
human tissues reveals an abundant 4.5-kb transcript 
in heart, placenta, and ovary tissue (Zhang et al., 
1994). 
Protein 
The open reading frame encodes a 1231 amino acid 
protein, with an estimated molecular weight of 
131,9 kDa.  
Fibulin-2 shares a structural multidomain complex 
architecture with the rest of the members of the 
fibulin family, specially with fibulin-1.  
This organization includes a signal peptide, a 
cystein rich domain, a cystein free domain, three 
anaphylotoxyn domains, an EGF-like (Epidermal 
Growth Factor) domain following the first out of a 
total of ten cbEGF (calcium-binding Epidermal 
Growht Factor) domains and finally, at the carboxy-
terminus the fibulin-like domain, characteristic of 
the fibulin family (Figure 1) (Timpl et al., 2003; de 
Vega et al., 2009; Obaya et al., 2012).  
An alternative splicing has been described for 
fibulin-2 mRNA by which exon 10 is removed 
resulting in a short fibulin-2 (FBLN2S) of 1184 
amino which lacks the third EFG-like domain in 
comparison to the long fibulin-2 (FBLN2L) (Zhang 
et al., 1994; Grassel et al., 1999; Law et al., 2012).  
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Figure 1. Fibulin-2 domain organization. EGF : Epidermal Growth Factor. 
 
 
It has been described that fibulin-2 forms anti-
paralel homodimers stabilized by a single disulfide 
bond throug a cysteine residue located in the second 
anaphylotoxin domain. As seen by electron 
microscopy, fibulin-2 homodimerization produces a 
set of star-like particles consisting in two-, three- or 
four-arm structures as well as some larger 
aggregates. Thus, the complexity of fibulin-2 
structure allows different combinations and 
possibilities to interact with other extracellular 
matrix proteins (Pan et al., 1993; Sasaki et al., 
1997). 
Expression 
Northern blot analysis of mRNA from various 
human tissues reveals the presence of fibulin-2 
transcript in heart, placenta and ovary tissue (Zhang 
et al., 1994). Fibulin-2 expression is restricted to 
certain tissues and partially overlaps with that of 
fibulin-1. Both proteins are localized in basement 
membranes, elastic fibers, and other connective 
tissue structures (Pan et al., 1993; Roark et al., 
1995; Miosge et al., 1996; Reinhardt et al., 1996; 
Zhang et al., 1996). Both proteins can be detected 
in early stages of embryonic development although 
fibulin-2 synthesis is delayed with respect to 
fibulin-1. However, both are at relatively high 
levels at the onset of organogenesis in mouse and 
humans (Miosge, 1996; Zhang et al., 1996). 
Fibulin-2 is expressed during the epithelial to 
mesenchymal transformation in the endocardial 
cushion matrix, aortic arch vessels and coronary 
vessels during embryonic heart development 
(Zhang et al., 1995; Tsuda et al., 2001). Fibulin-1 
and fibulin-2 are also expressed and deposited in 
several, although different neuronal structures. 
Specifically, fibulin-2 was detected primarily 
within the neuropithelium, spinal ganglia and 
peripheral nerves (Zhang et al., 1996). Furthermore, 
fibulin-2 has also been detected during skin wound 
healing, in the developing cartilage (perichondrium) 
or deposited in the organization of corneal 
structures (Zhang et al., 1995; Ducros et al., 2007; 
Kobayashi et al., 2007). 
Localisation 
Secreted, extracellular matrix. 
Function 
Fibulin-2 as well as other members of the fibulin 
family play essential role for the correct assembly 
of elastic fibers in connective tissues (Kielty et al., 
2002).  
In particular, fibulin-2 is localized in the interface 
between the two main components of elastic fibers, 
microfibrils and the elastin core (Reinhardt et al., 
1996; Kobayashhi et al., 2007). In its structural 
function, fibulin-2 is able to interact with several 
other extracellular components to maintain specific 
connective tissues properties. Thus, fibulin-2 is able 
to interact with troposlatin-2 (Sasaki et al., 1999), 
aggrecan and versican (Olin et al., 2001), 
fibronectin and nidogen-1 (Sasaki et al., 1995). All 
those bindings partners overlap with those of 
fibulin-1 but, fibulin-2 is also able to specifically 
interact with fibrillin-1 and perlecan (Reinhardt et 
al., 1996; Hopf et al., 2001). 
Fibulin-2 is also suggested to regulate steroid 
hormone action since it is able to interact with sex 
hormone globulin (SHBG) (Ng et al., 2006). 
Mutations in SHGB alter its binding capacities to 
fibulin-2 and sex hormones suggesting participation 
in human diseases (Wu and Hammond, 2014). In 
relation with steroid hormones, progesterone, 
dexamethasone, estradiol and glucocorticoids are 
able to regulate fibulin-2 expression levels in 
different tissues and contexts (Talts et al., 1995; Gu 
et al., 2001; Okada et al., 2003; Eyster et al., 2014 ; 
Olijnyk et al., 2014). 
Homology 
The FBLN2 gene is conserved in chimpanzee 
(Refseq: NC_006490.3), dog (Refseq: 
NC_006602.3), cow (Refseq: AC_000179.1), 
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mouse (Refseq: NC_000072.6), rat (Refseq: 
NC_005103.4), chicken (Refseq: NC_006099.3), 
and zebrafish (Refseq: NC_007122.5). 
Implicated in 
Various cancers 
Fibulin-2 was early related to cancer in a study 
aimed to look for genes differently expressed 
between adenocarcinoma metastases of multiple 
tumor types and the unmatched primary 
adenocarcinomas (breast, prostate, lung, colon, 
uterus and ovary) (Ramaswamy et al., 2003). 
Nasopharyngeal carcinoma 
Genome-wide Human Mapping Array analysis 
showed that the chromosome 3p25 region, where 
FBLN2 maps, is often deleted in esophageal 
squamous cell carcinoma patients (Chattopadhyay 
et al., 2010). More recently, fibulin-2 RNA 
downregulation has been described in 100% of 
nasopharingeal carcinoma cell lines as well as 
46.7% of biopsies tested. Deletion and promoter 
hypermethylation events contribute to the silencing 
of FBLN2 expression (Law et al., 2012). Functional 
analysis of fibulin-2 role as a tumor suppressor 
gene showed angio-inhibitory and tumor-
suppressive properties that are linked to a short 
isoform of FBLN2, FBLN2S, in nasopharingeal 
carcinoma (Law et al., 2012). Interestingly, 
FBLN2-associated anti-angiogenic activity is 
concomitant with a downregulation of two pro-
angiogenic factors such as VEGF and matrix-
metalloprotease-2 (MMP-2). 
Breast cancer 
Fibulin-2 was suggested to be a putative biomarker 
of breast cancer attending to the proteomic analysis 
performed in a breast cancer mouse model 
(Whiteaker et al., 2007). A role of fibulin-2 as a 
tumor suppressor gene in breast cancer came after 
the observation of its down-regulation in several 
cancer cell lines (Yi et al., 2007). Exogenous 
expression of fibulin-2 in breast cancer cell lines 
was able to reduce cell motility as well as invasion 
capacities, some of the tumor properties of those 
cells (Yi et al., 2007). One of the mechanisms to 
reduce FBLN2 gene expression is throuh promoter 
hypermethylation as it has been described in breast 
cancer cell lines (60%), primary breast tumors 
(34%) and matched tumor/normal pairs (32%) 
biopsies (Hill et al., 2010). Fibulin-2 might exert its 
tumor suppressor function by interaction with other 
proteins of the extracellular matrix as is the case of 
ADAMTS-12 (Fontanil et al., 2014). ADAMTS-12 
is a secreted metalloprotease (Cal et al., 2001; Cal 
and Obaya, 2014) and different studies have 
suggested a role for this metalloprotease in tissue 
remodeling and cell migration or adhesion (Noel et 
al., 2012). Fibulin-2/ADAMTS-12 interaction has 
been shown to inhibit the migration, invasion and 
tumorigenicity properties of cancer breast cell lines 
after exogenous expression of ADAMTS-12 
(Fontanil et al., 2014). 
Lung adenocarcinoma 
Based on the previous study of Ramaswamy et al. 
comparing primary a metastatic tumors in the 
search of a gene metastatic signature (Ramaswamy 
et al., 2003), a proteomic screen of highly and 
poorly metastatic tumor cell lines derived from 
mice that develop lung adenocarcinoma revealed 
that fibulin-2 was preferentially expressed in highly 
metastatic cells (Schliekelman et al., 2011). A more 
profound and functional study revealed that fibulin-
2 shows an oncogenic potential in lung 
adenocarcinoma (Baird et al., 2013). Fibulin-2 is 
found expressed in metastatic-derived cell lines and 
tumor growth depends on the endogenously 
expressed fibulin-2 since they are able to grow 
equally in Fbln2-null and wild-type mice. 
Furthermore, fibulin-2 requires the presence of 
collagen in the extracellular matrix in order to 
promote tumorigenic properties of these cells lines 
(Baird et al., 2013). 
Pancreatic cancer 
Expression of MUC4, a transmembrane type I 
glycoprotein, is elevated in pancreatic cancer. It is 
also known that MUC4 is able to interact through 
its nidogen-like domain with fibulin-2 and authors 
suggest that this association contributes to the 
MUC4-mediated metastasis of pancreatic tumor 
cells (Senapati et al., 2012). 
Kaposí's sarcoma 
Infection of dermal microvascular endothelial cells 
(DMVEC) with Kaposi's sarcoma-associated 
herpesvirus (KSHV) reduced fibulin-2 protein and 
RNA. Furthermore, a decrease in the expression of 
fibronectin and tropoelastin, binding partners of 
fibulin-2, was also detected in infected cells 
(Alcendor et al., 2011). Since downregulataion of 
other fibulins is observed, authors suggest that 
dysregulation of fibulin family members such as 
fibulin-2, fibulin-3, fibulin-5, fibulin 1C, and 
fibulin 1D likely contribute to KSHV-induced 
pathogenesis in Kaposi's sarcoma (Alcendor et al., 
2011). 
Various diseases 
Fibulin-2 participation in disease has been 
somehow elusive due to functional redundacy with 
other members of the fibulin family. Thus, fibulin-1 
staining is highly detected in the absence of fibulin-
2 in the viable, fertile and free of anatomic 
abnormalities fibulin-2 knock-out mice (Sicot et al., 
2008; Olijnyk et al.,2014). However, several studies 
support fibulin-2 functions in disease and cancer. In 
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the case of cancer, fibulin-2 shows a dual function, 
showing either suppresor gene or oncogenic 
activities (Obaya et al., 2012). 
Skin damage 
In normal skin, regulation of skin elastogenesis 
depends on the association between fibulin-2 and 
fibulin-5 with fibrillin-1 matrix (Lemaire et al., 
2004). Fibulin-2 is not only known to participate in 
the elastic structure of the skin but also participates 
in skin wound healing where it shows an increased 
expression with mRNA levels returning to normal 
after skin repair (Fässler el al., 1996). Fibulin-2 
deposition is also high in a mice model of chronic 
contact dermatitis as well as in models of solar 
elastosis which suggests a protective role of fibulin-
2 in skin formation and maintenance (Kusubata et 
al., 1999; Hunzelmann et al., 2001). Furthermore, 
fibulin-2 reduction in fbln2 null mice or due to the 
lack of integrin α3β1-laminin interaction 
contributes to loss of the integrity of basement 
membrane and skin blistering (Sicot et al., 2008; 
Longmate el al., 2014). In fact, the latest occurs 
since fibulin-2 is one of the genes regulated by 
integrin α3β1 in inmortalized keratinocytes and 
seems to be one of the mediators in the invasive 
capacities exerted by integrin α3β1 (Missan et al., 
2014). 
Cardiaovascular pathologies 
Fibulin-2 has been detected in the endocardial 
cushion tissue, endocardium and the basement 
membrane zones and adventitia of blood vessels of 
developing human and mouse embryo (Zhang et al., 
1995; Miosge et al., 1996). Fibulin-2 is also up-
regulated in transformed cells that migrate into the 
extracellular matrix of cardiac valves and aortic 
arch vessels and authors suggest that fibulin-2 is 
also required for the correct formation of coronary 
arteries and veins in postnatal life (Tsuda et al., 
2001). However, although mice lacking fibulin-2 do 
not show any obvious phenotypic anomalies (Sicot 
et al., 2008), loss of fibulin-2 significantly 
improved the survival rate after experimental 
myocardial infarction through attenuating 
progressive ventricular dysfunction accompanied 
by reduced activation of the TGFβ-dependent 
pathway (Tsuda et al., 2012). The modulation of 
this signalling pathway by fibulin-2 in heart 
homeostasis has also been described in an 
angiotensin II-induced heart hypertrophy model 
(Zhang et al., 2014). In both cases, fibulin-2 
deficiency results in a better outcome of the 
pathologies. 
Fibulin-2 is required, in cooperation with fibulin-5, 
in the maintenance of vessel integrity as well as in 
vessel recovery after injury (Chapman et al., 2010). 
In this regard, participation of fibulin-2 in artery 
integrity and stiffnes is also important in order to 
control blood pressure and it has been described the 
existence of some polymorphisms of FBLN2 
associated with reduced levels of systolic blood 
pressure and decreased risk of hypertension (Vallvé 
et al., 2012). 
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